You are here: Industry Insights > Celgene

News List

FDA Approves Inrebic (fedratinib) for the Treatment of Patients With Myelofibrosis drugs
August 19, 2019
Celgene Corporation announced the U.S. Food and Drug Administration (FDA) has approved Inrebic (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or ...
Bristol's Celgene buyout 'more important' given drug pricing pressure fiercepharma
July 28, 2019
The drug pricing debate is raging on in Washington, D.C., and that's part of the reason Bristol-Myers Squibb wants to nab Celgene, CEO Giovanni Caforio told analysts Thursday.
Celgene licenses antibody JTX-8064 from Jounce for $50m pharmaceutical-technology
July 25, 2019
Global biopharma company Celgene has updated its 2016 strategic collaboration with clinical stage-focused Jounce Therapeutics and has decided to license global rights to JTX-8064; Celgene will now be responsible for all development and commercialisation o
Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia drugs
June 11, 2019
Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia.
Evotec, Celgene Expand Strategic Alliance contractpharma
June 10, 2019
Expanded neurodegenerative alliance to include a new cell type, triggering $9.0 million payment to Evotec.
FDA approves Celgene’s R2 for two types of indolent lymphoma pharmaceutical-technology
May 30, 2019
Celgene has announced that the US Food and Drug Administration (FDA) has approved Revlimid (lenalidomide) in combination with rituximab (R2) for patients with ...
Celgene Receives EC Approval for Two Triplet Regimens Based on IMiD Treatments americanpharmaceuticalreview
May 23, 2019
Celgene announced the European Commission (EC) has approved two new triplet regimens based on Celgene’s proprietary IMiD treatments, REVLIMID (lenalidomide) and IMNOVID (pomalidomide).
Celgene’s Pomalyst secures breakthrough designation pharmaceutical-technology
May 16, 2019
The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to Celgene’s Pomalyst (pomalidomide) in HIV-positive and HIV-negative Kaposi sarcoma.
Don't worry about our $19B bond issue, BMS says. With Celgene, we'll have the cash to pay it off fiercepharma
May 09, 2019
Bristol-Myers Squibb is taking on a debt load to cover its $74 billion Celgene buyout, and it issued $19 billion in bonds Tuesday to help pay the bill.
Celgene Corporation and bluebird bio Announce Results from Ongoing Multicenter Phase 1 Study of bb2121 anti-BCMA CAR T Cell Therapy in Patients with Multiple Myeloma Published in New England Journal of Medicine drugs
May 08, 2019
Celgene Corporation (Nasdaq: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that the New England Journal of Medicine (NEJM) has published interim results from CRB-401 ...

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page